Based on these key observations and the significant anti-cancer activity of anti-Gal-9 antibodies, Gal-9 has become an attractive target for cancer therapy and Gal-9, either alone or in combination with TIM-3, plays a crucial role in maintaining immunosuppression within the tumor microenvironment. This evidence concerns the gene HAVCR2 and cancer.